Loading
A phase 2 trial of Isatuximab, Carfilzomib, Dexamethasone in multiple myeloma, run by Sanofi, active and no longer recruiting.
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT05704049 by Sanofi, with 118 participants enrolled, started 2023-04-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: Isatuximab, Carfilzomib, Dexamethasone, Dexamethasone IV, Montelukast. Conditions listed: Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Isatuximab, Antiemetics for chemotherapy-induced nausea and vomiting, Sanofi, Dexamethasone.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Isatuximab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/